Wall Street ended the week deeply divided, with technology-heavy indexes pushing higher while blue-chip and small-cap benchmarks struggled to maintain momentum.
The Nasdaq Composite closed at 27,190.86, gaining 1.19% on the day and extending its year-to-date advance to an impressive 16.99% for 2026.
The Dow Jones Industrial Average slid to 51,176.96, posting a weekly loss of 1.26% after touching a high of 51,780.50 and a low of 50,546.54 during the week.
The Dow’s RSI14 reading of 39.4 signals the blue-chip index is pushing toward oversold territory, even as it holds a 6.48% year-to-date gain.
The S&P 500 added 0.73% on the day to close at 7,722.72, sitting between its 10-day SMA support of 7,707.82 and resistance at 7,771.48.
The Russell 2000 inched up 0.94% to 2,832.90 but remains down for the week, with an RSI14 of 39.6 that mirrors the Dow’s hesitancy.
Gold rose 0.64% to $4,189.10 an ounce, silver jumped 3.76% to $62.24, while WTI crude slipped 0.58% to $90.58 a barrel.
The 10-year Treasury yield climbed 4 basis points on the day to 5.28%, representing a 10 basis point rise for the week, adding pressure to rate-sensitive sectors.
Raytheon, an RTX (NYSE: RTX) business, secured a five-year contract valued up to $24.4 billion for Standard Missile-6 interceptors, capable of both offensive and missile defense missions for the U.S. Navy.
“SM-6’s multi-mission capability is vital to our customer, and Raytheon is intensely focused on meeting the demand,” said Raytheon President Phil Jasper.
The FDA approved an expanded indication for Eli Lilly’s (NYSE: LLY) Jaypirca as a first-line treatment for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion.
In the BRUIN CLL-313 trial, the overall response rate reached 94% in the pirtobrutinib arm versus 81% in the comparator arm at a median follow-up of 28 months.
“This additional approval for Jaypirca, based on BRUIN CLL-313, marks a significant step forward, expanding its potential to reach more patients who may benefit,” said Jacob Van Naarden, executive vice president and president of Lilly Oncology.
International Business Machines Corporation (NYSE: IBM) faces a law firm investigation after shares fell 25% on July 14, 2026, erasing more than $68 billion in market capitalization following disclosure of a Z mainframe performance shortfall.
CEO Arvind Krishna acknowledged that “[w]hat played out was worse than our expectations, driven by a shortfall in our Z performance and the associated software stack, primarily in Transaction Processing.”
Integra LifeSciences Holdings Corporation (NASDAQ: IART) lowered its full-year 2026 revenue guidance to a range of $1.634 billion to $1.654 billion following a July flooding event at its Cincinnati facility.
“While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter,” said Stuart Essig, Chairman and CEO.
Trilogy Metals Inc. (NYSE American: TMQ) reported a cash balance of $31.2 million and closed a $35.6 million strategic equity investment from the Department of War on September 11, 2026.
“With a defined permitting timeline, the investment by the U.S. Government, and a clear line of sight to a Record of Decision, Arctic is well positioned to become a cornerstone of a secure, domestic copper supply chain,” said Tony Giardini, President and CEO.
